Long-Term Outcomes of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa: A Multicentre Cohort Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avallone Gianluca, Roccuzzo Gabriele, Valtellini Luca, Moltrasio Chiara, Genovese Giovanni, Repetto Federica, Aouadi Mohamed, Moglia Alessia, Manzo Margiotta Flavia, Schettini Natale, Martora Fabrizio, Gargiulo Luigi, Valenti Mario, Malvaso Dalma, Bernardini Nicoletta, Dattola Annunziata, Conforti Claudio, Marasca Claudio, Derlino Federica, Maronese Carlo Alberto, Giordano Silvia, Satolli Francesca, Dini Valentina, Bettoli Vincenzo, Megna Matteo, Costanzo Antonio, Peris Ketty, Skroza Nevena, Richetta Antonio Giovanni, Fania Luca, Quaglino Pietro, Pellacani Giovanni, Marzano Angelo Valerio, Ribero Simone
Аннотация
OBJECTIVE: To evaluate the long-term effectiveness, safety, and predictors of response to secukinumab in a real-world cohort of patients with moderate-to-severe HS.
METHODS: Multicentre retrospective cohort study across 12 Italian tertiary referral hospitals. The primary effectiveness outcomes were the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) and a 55% reduction in the International Hidradenitis Suppurativa Severity Score System (IHS4-55) at any time point.
RESULTS: A total of 77 patients (53% female; median age 38 years, interquartile range: 27-50) met the inclusion criteria. At week 52, 36.2% of patients achieved HiSCR and 55.6% achieved IHS4-55. The mean reduction from baseline to week 52 was 50.8% for skin pain Numeric Rating Scale and 55.2% for Dermatology Life Quality Index. Agreement between IHS4-55 and HiSCR was 76.6% (Cohen's kappa 0.5255; 95% CI: 0.4307-0.6202, P < .0001). Patients in Hurley stage 3 had a significantly lower hazard ratio (HR) of achieving IHS4-55 than those in Hurley stage 2 (HR 0.52; 95% CI: 0.31-0.89, P = .017), which persisted in the multivariable model (HR 0.56; 95% CI: 0.31-0.99, P = .044). No new safety concerns were identified.
CONCLUSIONS: This study suggests that secukinumab provides clinically meaningful long-term outcomes in HS management, even in bio-experienced patients.